Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Krystal Biotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Krystal Biotech's regulatory disclosures and financial reporting.
KRYS reported Form 144 sales by an insider. The filing lists recent sales of Common shares by Daniel S. Janney on 02/24/2026, 02/25/2026, and 02/26/2026, including transactions of 37,895 and 13,825 shares on 02/24/2026. The entries show cash proceeds for each trade in USD.
Krystal Biotech director Daniel Janney reported option exercises and share sales in Krystal Biotech, Inc. common stock. On February 24, 2026, he exercised stock options covering 37,895 shares and received the same number of common shares, then sold those shares in multiple open-market transactions.
On February 24 and 26, 2026, additional open-market sales were reported in accounts indirectly holding shares for Alta Bioequities, L.P., which is managed by an affiliated general partner. The filing notes that Janney’s option exercise and sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025. After these trades, 85,096 shares were held indirectly through Alta Bioequities, L.P., while no shares were held directly.
KRYS affiliate files Form 144 to sell common stock. The filing lists proposed/reported sales by Daniel S. Janney consisting of 37,895 shares, 13,825 shares and 700 shares with aggregate cash proceeds reported as $10,113,354.42, $3,709,850.15 and $192,500, respectively. Dates shown for the transactions are 02/24/2026 and 02/25/2026.
KRYS filing a Form 144 notice reports proposed sales of common stock by Daniel S. Janney. The filing lists a proposed sale of 37,895 shares for $10,113,354.42 and a proposed sale of 13,825 shares for $3,709,850.15, both dated 02/24/2026.
KRYS submitted a Form 144 notifying a proposed sale of Common stock, listing 37,895 shares to be sold through Fidelity Brokerage Services LLC by 02/24/2026 with a sale method labeled Cash.
The filing also shows securities sold during the past three months: 13,825 Common shares by Daniel S. Janney on 02/24/2026 for $3,709,850.15.
KRYS: Form 144 sale notice by Daniel S Janney for $10,113,354.42 proceeds on 02/24/2026. The filing lists the sale of 37,895 common shares and identifies the issuer contact as Merrill Lynch, 555 California Street, San Francisco. The securities trace to a private placement dated 08/25/2017.
Krystal Biotech, Inc. director Dino A. Rossi reported option exercises and related share sales. On February 19, 2026, he exercised stock options for 18,950 shares of common stock at $8.79 per share. The options vested ratably over four years beginning on June 1, 2018. On the same date, he sold 8,116 shares at $260.4858 and 10,834 shares at $262.10 in open-market transactions, totaling 18,950 shares sold. After these trades, he directly owned 78,691 shares of Krystal Biotech common stock.
Krystal Biotech reported strong fourth quarter and full year 2025 results, with full-year product revenue, net of $389.1 million and net income of $204.8 million, or $6.84 per diluted share. Fourth quarter product revenue reached $107.1 million, driving quarterly net income of $51.4 million, or $1.70 per diluted share. The company ended December 31, 2025 with $955.9 million in cash, cash equivalents, and investments, and generated a gross margin of 94% on VYJUVEK revenue. Krystal also highlighted global commercialization progress for VYJUVEK and advancement across its respiratory, ophthalmology, dermatology, oncology, and aesthetics pipelines, including FDA RMAT and Fast Track designations and multiple ongoing or planned registrational studies.
Krystal Biotech, Inc. provides an annual overview of its commercial-stage gene therapy business, centered on its HSV‑1-based redosable platform. The company’s first product, VYJUVEK, is approved in the United States, European Union, and Japan for dystrophic epidermolysis bullosa and has generated $730.3 million in net product revenue since launch.
Krystal is expanding VYJUVEK globally, with launches in Germany, France and Japan and additional distribution agreements across Europe and the Middle East. It reports broad clinical activity across respiratory, ophthalmology, dermatology, oncology and aesthetics programs, including inhaled KB407 for cystic fibrosis, KB408 for alpha‑1 antitrypsin deficiency, ocular candidates KB803 and KB801, dermatology program KB111, oncology asset KB707 for lung cancer, and aesthetic candidates KB304 and KB301.
The company emphasizes in‑house commercial‑scale CGMP manufacturing through its ANCORIS and ASTRA facilities, which support VYJUVEK supply and its broader pipeline. Krystal also highlights a growing global intellectual property estate around its HSV‑1 vector platform, commercial product and pipeline candidates.